FDA OKs Targeted Lung Cancer Rx
The US Food and Drug Administration (FDA) has approved a targeted drug for a type of non-small cell lung cancer.
A Drop in Lung Cancer Deaths
Deaths from the most common type of lung cancer have decreased rapidly in recent years. Researchers are saying new treatments are behind this good news.
FDA Approved Treatment Option - Non Small Cell Lung Cancer
An Approved Treatment Option For Previously Treated Advanced NSCLC. Learn More.
Lung Cancer Rx Receives FDA Approval
A lung cancer drug has received regular approval from the US Food and Drug Administration (FDA).
Tecentriq Gets a New Job
The US Food and Drug Administration has approved Tecentriq (atezolizumab) to treat advanced lung cancer.
A New Job for Xalkori
The US Food and Drug Administration (FDA) approved Xalkori (crizotinib) to treat patients with advanced non-small cell lung cancer (NSCLC) who have tumors with an ROS-1 gene alteration.
A New Option for ALK-Positive Lung Cancer
The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).
FDA OKs Lung Cancer Rx Portrazza
The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.
FDA Approves New Lung Cancer Rx
On November 13, 2015, the U. S. Food and Drug Administration granted accelerated approval to osimertinib (TAGRISSO) once daily tablets, AstraZeneca Pharmaceuticals LP, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
FDA Expands Opdivo Approval
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
- Xalkori (9) Apply Xalkori filter
- Tarceva (8) Apply Tarceva filter
- Abraxane (2) Apply Abraxane filter
- Avastin (2) Apply Avastin filter
- Erbitux (2) Apply Erbitux filter
- Taxotere (2) Apply Taxotere filter
- Caprelsa (1) Apply Caprelsa filter
- Herceptin (1) Apply Herceptin filter
- Iressa (1) Apply Iressa filter
- Nexavar (1) Apply Nexavar filter
- Perjeta (1) Apply Perjeta filter
- Provenge (1) Apply Provenge filter
- Toprol XL (1) Apply Toprol XL filter
- Tykerb (1) Apply Tykerb filter
- (-) Remove Cancer filter Cancer
- Mental Health (4) Apply Mental Health filter
- Mens Health (3) Apply Mens Health filter
- Womens Health (3) Apply Womens Health filter
- Dermatology (1) Apply Dermatology filter
- Healthy Eating and Diet (1) Apply Healthy Eating and Diet filter
- Pulmonary Disease (1) Apply Pulmonary Disease filter